Asia-Pacific Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2030.
Asia-Pacific Fibrotic Diseases Treatment Market Analysis and Insights
Asia-Pacific fibrotic diseases treatment market is driven by the factors such as the rising prevalence of fibrotic diseases, an increase in the number of people smoking cigarettes, and technological advancement in the treatment of fibrosis diseases, leading to market growth. Currently, healthcare expenditure has increased across developed and emerging countries which is expected to create a competitive advantage for manufacturers to develop new and innovative products.
Asia-Pacific fibrotic diseases treatment market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for the safe distribution of machine and drug products are the major drivers which propelled the demand of the market in the forecast period.
Asia-Pacific fibrotic diseases treatment market is supportive and aims to reduce the progression of the diseases. Data Bridge Market Research analyses that the Asia-Pacific fibrotic diseases treatment market will grow at a CAGR of 6.0% during the forecast period of 2022 to 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2015- 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, Pricing in USD, Volume in Units
|
|
Segments Covered
|
By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific
|
|
Market Players Covered
|
Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., and Sandoz International GmbH among others
|
Market Definition
The term fibrosis describes the development of fibrous connective tissue as a reparative response to injury or damage. Fibrosis may refer to the connective tissue deposition that occurs as part of normal healing or to the excess tissue deposition that occurs as a pathological process. Diseases characterized by uncontrolled, progressive fibrosis include Idiopathic Pulmonary Fibrosis (IPF), Non-Alcoholic Steatohepatitis (NASH), and Systemic Sclerosis (SSc).
Fibrosis is a group of serious organ/tissue diseases that affect the tissue system. Fibrosis scars and thickens the tissue. It impacts the connecting tissue, for instance, in the lung and the alveoli (air sacs inside the lungs). The lung damage gradually gets worse over time. Hard, stiff lung tissues don't expand as well as they should, making it harder to breathe. Pulmonary fibrosis may cause shortness of breath when you do routine tasks that never seemed tiring before.
Asia-Pacific Fibrotic Diseases Treatment Market Dynamics
Drivers
- Rising prevalence of fibrotic diseases
Due to various risk factors such as aging, obesity, high blood pressure (hypertension), or family history of fibrotic disease, patients with fibrotic diseases are rising globally and becoming a significant socio-economic issue. Thus, the rising number of patients with fibrotic diseases increases the demand for treatment, which act as a driver in the fibrotic diseases treatment market.
- Increase in the number of people smoking cigarettes
Cigarette smoking is one of the most recognized risk factors for the development of Idiopathic Pulmonary Fibrosis (IPF). Furthermore, recent work suggests that smoking may have a detrimental effect on the survival of patients with IPF. The mechanism by which smoking may contribute to the pathogenesis of IPF is largely unknown. However, accumulating evidence suggests that increased oxidative stress might promote disease progression in IPF patients who are current and former smokers.
Thus cigarette smoke contains particulate matter as well as numerous chemicals, including highly toxic RONS, which increases the swelling inside the body and hence lead to various diseases, including pulmonary fibrosis, cancer among others, which is expected to drive the growth of fibrotic diseases treatment market.
- Technological advancement in the treatment of fibrosis diseases
IPF is characterized by the progressive accumulation of scar tissue in the lung and is associated with a median life expectancy of 2–4 years. Until recently, treatment options were limited, focusing on ineffective anti-inflammatory therapy, palliation, transplant, or trial recruitment. Significant recent advances in the field have led to two novel anti-fibrotic agents, pirfenidone and nintedanib, which have been shown to significantly slow disease progression in IPF.
Thus increasing technological advancements for the detection and treatment of fibrotic diseases is expected to drive the growth of the fibrotic diseases treatment market.
Opportunities
- Rising research and development activities
The research and development activities have significantly opened various ways for the treatment of several diseases. The emerging technological advancements, along with the appropriate research, lead to the formation of several drugs for the treatment of diseases. Most people associate a company's research and development function with the invention of new products. While inventions are important, the development of existing products is of equal significance as consumer preferences are continually changing.
Thus, rising research and development activities for fibrotic disease medications and treatment are expected to act as opportunities for the growth of the fibrotic diseases treatment market.
- Development of new and more effective therapies for fibrotic diseases
There are very few treatment options available for fibrotic diseases. These include medication which includes pirfenidone and nintedanib, oxygen therapy, organ transplantation, and pulmonary rehabilitation.
Hence the rising development of new and more effective therapies for fibrotic diseases will provide new opportunities in the fibrotic diseases treatment market.
Restraints/Challenges
- High cost of medication and treatments
Fibrotic disease treatments have become increasingly expensive due to the growing number of patients suffering from fibrosis and the risen prices of medical devices and medications. The modern technological devices used in fibrosis treatment are also playing a significant role in the high prices of treatments, and high accuracy, providing a definitive diagnosis for Idiopathic Pulmonary Fibrosis (IPF). Therefore, the high cost of medications and treatment procedures for fibrotic disease is hampering the market's growth.
Hence, the high cost associated with the medication and treatment of fibrotic disease is expected to restrict the growth of the fibrotic diseases treatment market.
- Lack of effective biomarkers and diagnostic tools for early detection and monitoring of fibrotic diseases
Biomarkers can be measurements of physiological and pathological processes or drug effects. For instance, they can distinguish the disease from health or other similar diseases (a diagnostic); they can predict mortality, exacerbation, and disease progression (a prognostic); and as well as predict a response to therapy (a theranostic).
Therefore, the limited availability of chest imaging in developing countries is considered a chief obstacle to diagnosis since high-resolution computed tomography of the chest is the key diagnostic test for Idiopathic Pulmonary Fibrosis (IPF). Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries, which is expected to restrain the growth of the fibrotic diseases treatment market.
- The complex and multifactorial nature of fibrotic diseases.
Although complex fibrotic disorders often cluster in families, they do not have a clear-cut pattern of inheritance. It may be difficult to identify the role of genetics in these disorders, particularly because families often also share environments and may have similar lifestyles. This makes it difficult to determine a person's risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified.
Hence the complex and multifactorial nature of fibrotic disease is expected to challenge the fibrotic diseases treatment market.
Recent Development
- In May 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and ArisGlobal, the Asia-Pacific market leader in drug safety solutions worldwide, announced the acquisition of Boehringer Ingelheim's digital innovation, BRASS, by ArisGlobal. This data insights engine will be integrated into ArisGlobal's technology platform, LifeSphere, under the name of LifeSphere Clarity and will play a key role in driving industry-wide advancement of pharmacovigilance and patient safety. This has helped the company to expand its clinical diagnostics business across various regions in the world and helped to increase the Asia-Pacific presence in the market
- In March 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement under which Bristol Myers Squibb acquired Turning Point Therapeutics for USD 76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and was anticipated to close during the third quarter of 2022. This acquisition has helped the company to increase its Asia-Pacific presence in the market.
Asia-Pacific Fibrotic Diseases Treatment Market Segmentation
The Asia-Pacific fibrotic diseases treatment market is categorized into four notable segments based on treatment, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Treatment
- Medication
- Organ Transplantation
- Oxygen Therapy
- Others
On the basis of treatment, the fibrotic diseases treatment market is segmented into medication, organ transplantation, oxygen therapy, and others.
Application
- Idiopathic pulmonary fibrosis
- Hepatic cirrhosis
- Renal fibrosis
- Cutaneous fibrosis
- Others
On the basis of application, the fibrotic diseases treatment market is segmented into idiopathic pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others.
End User
- Government organization
- Hospitals
- Academic and research institutes
- Others
On the basis of end user, the fibrotic diseases treatment market is segmented into hospitals, specialty clinics, academic and research institutes, and others.
Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Others
On the basis of distribution channel, the fibrotic diseases treatment market is segmented into hospital pharmacy, retail pharmacy, and others.
Asia-Pacific Fibrotic Diseases Treatment Market Regional Analysis/Insights
The Asia-Pacific fibrotic diseases treatment market is analyzed, and market size insights and trends are provided by treatment, application, end user, and distribution channel, as referenced above.
The countries covered in the Asia-Pacific fibrotic diseases treatment report are Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, and rest of Asia-Pacific.
Japan is expected to dominate the Asia-Pacific fibrotic diseases treatment market due to increasing technological advancement in developing areas.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Fibrotic Diseases Treatment Market Share Analysis
Asia-Pacific fibrotic diseases treatment market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the Asia-Pacific fibrotic diseases treatment market.
Some players in the Asia-Pacific fibrotic diseases treatment market are Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., and Sandoz International GmbH among others.
SKU-